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ABSTRACT
Objectives: Previous studies suggest that smokers
have a misperception of their 10-year cardiovascular
risk. We aimed to compare 10-year cardiovascular risk
self-perception and calculated risk among smokers
willing to quit and assess the determinants of a
possible misperception.
Design: Cross-sectional secondary analysis of
baseline data from a randomised controlled trial of
smoking cessation.
Participants: 514 participants, mean age 51.1 years,
46% women, 98% Caucasian. Eligible participants
were regular smokers, aged between 40 and 70 years,
with a consumption of at least 10 cigarettes per day
for at least a year. None of them had experienced
cardiovascular disease before. Exclusion criteria
comprised a history of myocardial infarction, coronary
heart disease, stroke, heart failure, peripheral vascular
disease, carotid atherosclerosis or cardiac arrhythmia.
Participants with renal or liver failure, psychiatric
disorders, substance and alcohol abuse and with
smoking cessation therapies were excluded.
Interventions: Participants were asked to estimate
their 10-year cardiovascular risk using a 3-item scale
corresponding to high-risk, moderate-risk and low-risk
categories. We compared their risk perception with
Framingham and Prospective Cardiovascular Munster
Study (PROCAM) scores. We used multivariable-
adjusted logistic regression models to determine
characteristics of participants who underestimate their
risk versus those who correctly estimate or
overestimate it.
Results: Between 38% and 42% of smokers correctly
perceived their 10-year cardiovascular risk, and
39–50% overestimated their 10-year cardiovascular
risk while 12–19% underestimated it compared with
their calculated 10-year cardiovascular risk depending
on the score used. Underestimation of 10-year
cardiovascular risk was associated with male gender
(OR 8.16; CI 3.83 to 17.36), older age (OR 1.06; CI
1.02 to 1.09), and the presence of hyperlipidaemia
(OR 2.71; CI 1.47 to 5.01) and diabetes mellitus
(OR 13.93; CI 3.83 to 50.66).
Conclusions: Among smokers, misperception of
their 10-year cardiovascular risk is common, with
one-fifth underestimating it. These findings may help
physicians target patients with such characteristics to
help them change their health behaviour and
adherence to risk-reduction therapy.
Trial registration number: NCT00548665;
Post-results.
INTRODUCTION
Cardiovascular disease (CVD) is the leading
cause of death worldwide. Ischaemic heart
disease and stroke are responsible for 13.2%
and 11.9% of deaths, respectively.1 Smoking
is the most important modiﬁable risk factor
Strengths and limitations of this study
▪ This study carefully assessed self-perceived car-
diovascular disease (CVD) risk among smokers
and compared self-perception with two validated
cardiovascular scores in a cross-sectional sec-
ondary data analysis of baseline data collected in
a randomised controlled trial assessing the effect
of carotid plaque screening on smoking
cessation.
▪ The study highlights predictors of underestima-
tion of CVD risk among smokers: male gender,
older age, and the presence of hyperlipidaemia
and diabetes mellitus.
▪ The analyses are restricted to smokers and no
comparison is possible between CVD perception
of smokers, non-smokers or former smokers.
▪ The analyses are restricted to smokers who
underestimated their cardiovascular risk and pre-
dictors of overestimation were not assessed.
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for CVD and smoking cessation prevents cardiovascular
mortality and morbidity in a rapid and effective
manner.2 Thus, the main strategy for CVD prevention is
based on controlling modiﬁable risk factors such as
smoking through population-wide interventions. These
include smoking bans in public places, tax raises on cig-
arette packs as well as individual healthcare interven-
tions such as counselling and medication for smokers
willing to quit.
An adequate perception of CVD risk might be
required to better understand the goal of preventive
interventions and adhere to CVD prevention. Studies
assessing CVD risk using questionnaires, registration
form, visual analogue scale and self-rated measurements,
conducted in general practices by Frijling et al3 and van
der Weijden,4 have suggested that smoking predicted
higher levels of risk perception. Smokers’ perception of
health risks is complex and underestimation or overesti-
mation of CVD risk depends on how risk perception is
assessed.5 For instance, Weinstein5 has reported that
smokers consistently acknowledged that smoking
increased their risk of developing heart disease, lung
cancer, bronchitis and stroke but within a smaller range
compared with non-smokers. Furthermore, smokers
tended to minimise their health risks. Individual misper-
ception of smokers has also been described in another
study that showed that only 29–39% of smokers per-
ceived themselves at higher risk than the average for
myocardial infarction.6 One could argue that smoking,
as part of a complex addiction mechanism, might be the
cause of misperception but CVD risk is also difﬁcult to
assess for physicians.7 To the best of our knowledge, few
studies focused on CDV risk perception among
smokers,3 4 and little or no information about CVD risk
(calculated by scores) was provided.
Prediction scores such as Framingham,8 PROCAM9 or
European Scores10 have been developed to estimate the
10-year CVD risk. These prediction models are increas-
ingly used to identify high-risk patients who would
beneﬁt from interventions on one or several risk factors
and to motivate others to adhere to risk-reduction
therapy. Based on previous publications, the PROCAM
score seems to be the most appropriate score in
Switzerland.9 11 However, the Framingham score is still
often used for clinical or research purposes (it is the
one used in International Lipid guidelines12) despite its
tendency to overestimate the cardiovascular risk in
European populations.
Awareness of CVD risk associated with cigarette
smoking might have changed during the past two
decades with more prevention and information cam-
paigns. Moreover, whether smokers have a correct per-
ception of their own CVD risk compared with calculated
CVD risk prediction scores has never been assessed and
little is known about determinants that could explain
the potential misperception of smokers.
The primary objective of this study was to assess the
accuracy of perception of CVD risk among smokers and
identify determinants associated with potential misper-
ception in a single-centre study conducted with smokers
in Switzerland.
METHODS
Study population
We did a cross-sectional secondary analysis of the base-
line data of the CAROtid Plaque Screening on Smoking
cessation (CAROSS) trial, a randomised controlled trial
assessing the effect of carotid plaque screening on
smoking cessation.13 Participants were recruited in the
general population using advertisements in newspapers
in multiple recruitment waves.
Eligible participants were regular smokers, aged
between 40 and 70 years, with a consumption of at least
10 cigarettes per day for at least a year and no periods of
smoking abstinence of at least 3 months in the previous
year. None of them had experienced CVD before, as
exclusion criteria comprised a history of myocardial
infarction, coronary heart disease, stroke, heart failure,
peripheral vascular disease, carotid atherosclerosis or
cardiac arrhythmia. Participants with renal or liver
failure, psychiatric disorders, substance and alcohol
abuse, and those taking smoking cessation therapies
were also excluded.
All participants provided written informed consent.
The study was approved by the local ethic commission of
the University of Lausanne, Switzerland.
Variables of interest
Data on medical and smoking history, home and work
environment, education and medication use were col-
lected using questionnaires. At baseline, a nurse trained
in smoking cessation asked each participant about his or
her perception of CVD risk. The question was standar-
dised to avoid inﬂuencing the participants and worded
as: ‘How do you perceive your risk of heart attack in
10 years?’. The possible responses were ‘none or low
risk’, ‘intermediate risk’, ‘high risk’, ‘don’t know’ and
‘refuse to answer’. Participants who ‘did not know’ or
‘refused to answer’ were invited once to reconsider their
choice. In this study, we restricted the analysis to partici-
pants who answered the self-perceived CVD risk question
and had complete baseline data.
To determine the reliability and reproducibility of the
CVD risk perception assessment, we asked a consecutive
convenience subsample of participants (n=48) to
reassess their CVD risk 1 month after the last evaluation.
We calculated Framingham scores based on ATP III
guidelines.14 We used the following variables at baseline to
calculate the score: sex, age, cholesterol, smoking status,
blood pressure, high-density lipoprotein (HDL)-
cholesterol, triglyceridaemia and being treated with anti-
hypertensive drugs. The Framingham score was then
encoded and CVD risk was computed for each participant.
According to Framingham scores, men with scores
≤11 were classiﬁed as low risk (10-year risk of
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cardiovascular events 8%), those with scores between 12
and 14 as intermediate risk (10-year risk of cardiovascu-
lar events 10–16%), and those with scores ≥15 as high
risk (10-year risk of cardiovascular events ≥20%). For
women, low, intermediate and high risk corresponded
to Framingham risk scores of 19 (10-year risk of cardio-
vascular events 8%), 20–22 (10-year risk of cardiovascu-
lar events 11–17%) and ≥23 (10-year risk of
cardiovascular events ≥22%) points, respectively.
The following variables at baseline were used to calcu-
late the PROCAM score: sex, age, low-density lipoprotein
(LDL)-cholesterol, HDL-cholesterol, triglyceridaemia,
blood pressure, diabetes, CVD before age 60 years
among relatives. The PROCAM score was encoded based
on a PROCAM study9 and CVD risk was computed for
each participant. Low, intermediate and high risk was
deﬁned as 10-year risk of cardiovascular events of <10%,
between 10–20% and ≥20%, respectively. By convention,
women had their risk divided by four.
Professional activity was initially classiﬁed as
‘employed’, ‘unemployed or on social security’ and
‘retired’. For the need of the multivariable-adjusted ana-
lysis and assuming that ‘retired’ participants were once
‘employed’, we secondarily merged ‘employed’ and
‘retired’ participants and obtained two categories
‘employed or retired’ and ‘unemployed or on social
security’. Education was dichotomised by <12 and
≥12 years of education. Both of these variables were
used as a proxy for socioeconomic status.
Weight and height were measured at baseline as well
as blood pressure in a sitting position with an appropri-
ately sized cuff according to guidelines. Fasting glucose
and lipid levels were measured at baseline. We deﬁned
cardiovascular risk factors as follows: hypertension as
≥140 systolic mmHg and/or 90 diastolic mmHg15,
except for participants with diabetes mellitus ≥130 and/
or 80 mm Hg; hyperlipidaemia according to ATP-III
guidelines16 as LDL-cholesterol ≥2.6 mmol/L,
≥3.4 mmol/L, ≥4.1 mmol/L for high-risk (>20%),
moderate-risk (10–20%) and low-risk (<10%) partici-
pants, respectively; and diabetes mellitus as fasting blood
glucose ≥7.0 mmol/L.17
Statistical analysis
The primary outcome was misperception of CVD risk.
For statistical convenience, we merged participants who
correctly estimate or overestimated their risk together,
believing that correct estimation or overestimation is less
detrimental than underestimation in terms of preventive
medicine. We compared participants who underesti-
mated their 10-year CVD risk with those who correctly
estimate or overestimated it. The comparison between
the baseline characteristics of both groups was per-
formed using χ2 tests and analysis of variance (ANOVA)
or Fisher tests.
We ﬁrst used univariable logistic regression to obtain
the OR and 95% CIs and identify potential predictors of
underestimation, compared with correct estimation or
overestimation of 10-year CVD risk. Variables that were
signiﬁcant with a p value <0.05 (sex, age, education,
working status, hypertension, hyperlipidaemia, diabetes,
cardiovascular medication) were then integrated in a
multivariable-adjusted analysis. Multivariable-adjusted
logistic regression was used to identify variables asso-
ciated with underestimation of the CVD risk compared
with correct estimation or overestimation.
We considered p values <0.05 as signiﬁcant. All data
were processed with STATA V.10 software (StataCorp,
College Station; Texas, USA).
RESULTS
The study included 536 participants, among whom 22
(4%) had incomplete baseline data (18 without self-
perceived CVD risk, and 4 whose high triglycerides pre-
vented calculation of LDL-cholesterol level). Among the
514 remaining participants, 98% were Caucasians and
234 (46%) were female (table 1). Mean age at baseline
was 51.1±7.3 years. Most participants were employed or
retired (92%), the rest being unemployed or on social
security. About two-third had lower education (<12 years;
apprenticeship or no education). Participants were
smoking an average of 24.5 (9.8 SD) cigarettes per day
for a mean duration of tobacco smoking of 32.1 (7.9
SD) years, corresponding to 39 (20 SD) pack-years. Two
hundred and ﬁfty-eight (50%) participants had hyperlip-
idaemia, whereas 27% had hypertension and 3.5% had
diabetes.
Using the Framingham score, half of the participants
(51%) were classiﬁed as low risk at 10 years, 38% as
intermediate risk and 11% as high risk (table 2). Using
the PROCAM risk score, the proportion of low-risk parti-
cipants was 76%, medium risk 13% and high risk 11%
(table 3). Participants perceived themselves at low risk
for 38% of them, intermediate risk for 34% and high
risk for 28% of them, using the self-perceived CVD risk
questionnaire. In a subsample of 48 participants,
reassessment of CVD risk perception (by telephone,
1 month after the initial evaluation) showed 83% of con-
sistent answers (40/48) (data not shown).
According to the Framingham score, less than half of
the participants (42%) correctly estimated their CVD
risk, 39% overestimated it and 19% underestimated it
(table 2). According to the PROCAM score, 38% cor-
rectly estimated their CVD risk, 50% overestimated it
and 12% underestimated it (table 3).
Among high-risk participants, 62–69% underestimated
their CVD risk (depending on the score used), whereas
33–34% underestimated it among intermediate-risk par-
ticipants (tables 2 and 3).
Using the Framingham score, male gender (OR 9.45; CI
4.9 to 18.2), older age (OR 1.05; CI 1.02 to 1.08), body
mass index (BMI) (OR 1.09; CI 1.03 to 1.14), hyperlipid-
aemia (OR 5.71; CI 3.34 to 9.76), diabetes (OR 9.27; CI
3.39 to 25.38) and being on CVD medication (OR 1.75; CI
1.08 to 2.82) were associated with underestimation of CVD
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risk in univariate analysis (data not shown). In the
multivariable-adjusted analysis, underestimation of CVD
risk was associated with male gender (OR 8.16; CI 3.83 to
17.36), older age (OR 1.06; CI 1.02 to 1.09), hyperlipid-
aemia (OR 2.71; CI 1.47 to 5.01) and diabetes mellitus
(OR 13.93; CI 3.83 to 50.66) (ﬁgure 1). We found no asso-
ciation between underestimation and BMI, socioeconomic
status, hypertension or being under CVD medication in
the multivariable-adjusted analysis. Using the PROCAM
risk score, we found similar results (table 4).
Table 1 Characteristics of study participants
Overall (n=514)
Demographics
Age (years) (mean± SD) 51.1 7.3
Women (n, %) 234 45.5
Education (n, %)
<12 years 381 74.1
≥12 years 133 25.9
Professional activity (n, %)
Employed* 433 84.2
Unemployed or on social security 40 7.8
Retired 41 8.0
Cardiovascular medication (n, %)
No treatment 390 75.9
Aspirine, statine, anti-HTA, anti-diabetic 124 24.1
Cardiovascular variables
Systolic blood pressure (mmHg± SD) 123.0 15.4
Systolic blood pressure (per 10 mm Hg)
Categories (n, %)
Low blood pressure† 376 73.2
High blood pressure† 138 26.8
BMI (kg/m2) (mean±SD) 24.9 4.1
Hyperlipidaemia‡ (n, %) 258 50.2
Treated (n, %) 60 11.7
Diabetes type 2§ (n, %) 18 3.5
Tobacco smoking
Number of cigarettes per day (mean±SD) 24.5 9.8
Number of pack-years (py±SD) 39 20
Fagerström score for nicotine dependence mean±SD
(0 low dependence–10 very high dependence)
5.0 2.1
*Full time, part time, independent or at home.
†Low blood pressure defined as <140/90 mm Hg; high blood pressure defined as ≥140 and/or 90, ≥130 and/or 80 mm Hg if diabetic.
‡Definition of hyperlipidaemia:
▸ Any treated patient (statin or fibrate);
▸ For high-risk patients when LDL-cholesterol ≥2.6 mmol/L;
▸ For intermediate-risk patients when LDL-cholesterol ≥3.4 mmol/L;
▸ For low-risk patients when LDL-cholesterol ≥4.1 mmol/L.
§Fasting glycaemia ≥7 mmol/L or glycaemia ≥11.1 mmol/L.
BMI, body mass index; LDL, low-density lipoprotein; HTA, hypertension.
Bold figures in this table refer to the standard deviation or percentage depending on the variable.
Table 2 Meshing table between perceived CVD risk and calculated CVD risk according to the Framingham score
Perceived CV risk T0
Framingham risk score
TotalLow Intermediate High
Low risk 111 64 22 197 (38.3)
Intermediate risk 79 81 14 174 (33.8)
High risk 70 51 22 143 (27.8)
Total 260 (50.5) 196 (38.1) 58 (11.2) 514 (100)
Numbers in absolute; () is percentage of total, in column.
Underestimated CVD risk 19%.
Correctly estimated CVD risk 42%.
Overestimated CVD risk 39%.
CV, cardiovascular; CVD, cardiovascular disease.
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DISCUSSION
In the present study, between 58% (for the Framingham
score) and 62% (for the PROCAM score) of participants
had a misperception of their CVD risk at 10 years.
Results were almost similar when low, intermediate and
high CVD risk categories were taken separately. A minor-
ity of participants (12–19%) underestimated their CVD
risk, whereas 39–50% overestimated it, depending on
the score used for the evaluation of cardiovascular risk.
Only 3% of participants could not provide an estimation
of their CVD risk.
A majority of participants had inadequate perception
of CVD risk, which is consistent with previous studies. In
our study, the CVD risk was perceived inappropriately in
62–69% of high CVD risk participants and 57–61% of
low-risk participants, whereas van der Weijden et al4
found that 80% of high-risk and 20% of low-risk partici-
pants had a misperception of their CVD risk in general
practices.
The use of the PROCAM risk score generated a
higher proportion of low-risk participants compared
with the Framingham risk score, but a lower proportion
of medium-risk participants. The proportion of high-risk
participants was similar using both scores. As a conse-
quence, compared with Framingham, a smaller propor-
tion of participants underestimated their CVD risk when
Figure 1 Determinants of underestimation (Framingham). ‘The ORs and respective 95% CIs are presented on a log scale.
Values above 1.0 (right of the dashed vertical line) present an increased risk of underestimating cardiovascular risk according to
Framingham risk score,8 while values below 1.0 (left of the dashed line) present a decreased risk of underestimating
cardiovascular risk. All characteristics were analysed as categorical variables, except for age in years as a continuous variable.
The presence of hypertension was defined as a blood pressure ≥140/90 mm Hg in patients without diabetes and ≥130/
80 mm Hg in patients with diabetes. The presence of hyperlipidaemia was defined according to the level of cardiovascular risk:
the threshold for patients with high, intermediate and low cardiovascular risk was ≥2.6 mmol/L, ≥3.4 mmol/L and ≥4.1 mmol/L,
respectively. The presence of diabetes was defined by levels of fasting glucose ≥7 mmol/L or glucose at any time ≥11.1 mmol/L.
Obesity was defined as a body mass index ≥30 kg/m2 (weight in kilograms divided by height in meters squared)’.
Table 3 Meshing table between perceived CVD risk and calculated CVD risk according to the PROCAM score.
Perceived CV risk T0
PROCAM risk score
TotalLow Intermediate High
Low risk 153 23 21 (38.3)
Intermediate risk 130 27 17 174 (33.8)
High risk 109 17 17 143 (27.8)
Total 392 (76.3) 67 (13.0) 55 (10.7) 514 (100)
Numbers in absolute; () is percentage of total, in column.
Underestimated CVD risk 12%.
Correctly estimated CVD risk 38%.
Overestimated CVD risk 50%.
CV, cardiovascular; CVD, cardiovascular disease.
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using the PROCAM risk score (61 vs 100 participants,
respectively), probably reﬂecting a better accuracy of
this score in a European population. Table 4 compares
the determinants of underestimation of the cardiovascu-
lar risk as calculated with Framingham or PROCAM
scores. Of note, important differences between CIs
width occurs in the male gender and diabetes variables
in PROCAM compared with Framingham. Interestingly,
these two variables remain statistically signiﬁcant even
though the strengths of association were less robust
mainly due to the smaller proportion of participants in
PROCAM and the few patients with diabetes in our
study (n=18). In fact, both of these scores consider type
2 diabetes as a high CVD risk regardless of other factors.
Thus, patients with diabetes were automatically consid-
ered in the highest risk category, which could explain
why diabetes has such a high OR. Further studies in a
population with diabetes speciﬁcally are needed.
We found that older age, male gender, hyperlipid-
aemia and diabetes were determinants of underestima-
tion of CVD risk. Our results contrast at least with two
other studies. Three quarter of participants with hyper-
tension or diabetes overestimated their CVD risk in the
study of Frijling et al.3 Similarly, van der Weijden et al4
highlighted that men and participants with diabetes
were more likely to perceive their CVD risk inappropri-
ately. However, caution is advised when comparing these
studies because the design and the baseline population
differ substantially. First, only 29% and 20% of partici-
pants were smokers in the studies of van der Weijden
et al and Frijling et al, respectively. Second, participants
in our study responded to an advertisement inviting them
to a study to help them quit smoking, whereas Frijling
et al gave questionnaires to patients visiting the general
ofﬁce who fulﬁlled inclusion criteria. The fact that the
participants in our study needed to actively respond to an
advertisement in order to be recruited might explain why
motivation, as well as health awareness, might have been
higher in the participants of this study than in the
general population of long-term smokers who do not
want to quit. This could also explain the low percentage
of participants who failed to provide an estimation
(correct or wrong) of their CVD risk.
Interestingly, more participants overestimated their
CVD risk (too pessimistic) than underestimated it in our
study. Nonetheless, we decided to focus on those who
underestimated their CVD risk (too optimistic), assum-
ing it to be more detrimental than overestimation. In
our opinion, underestimation of CVD risk might
decrease compliance with treatment or lifestyle modiﬁ-
cations as well as reduce the efﬁcacy of primary preven-
tion and thus increase the absolute risk of CVD event.
Overestimation may cause increased stress, medical
seeking or overmedication, which can affect the quality
of life rather than the absolute CVD risk.
To our surprise, diabetes was a determinant of under-
estimation of CVD risk, even though participants with dia-
betes presumably have had regular medical interaction
and lifestyle education. However, caution is advised consid-
ering the small proportion of participants with diabetes
(4%) in our study. Hyperlipidaemia was also a determin-
ant of underestimation, whereas other CVD risk factors
such as hypertension or BMI were not associated with
underestimation. Finally male gender was also associated
with higher odds of underestimation. Studies suggest that
men are less health conscious compared with women and
might be less susceptible to seek medical help.18
Our study carefully assessed self-perceived CVD risk
among smokers and compared it with two validated
calculated risk score. However, since our study was
limited to current smokers, we could not compare
smokers’ misperception with that of non-smokers or
former smokers. It would be interesting to assess risk
perception among non-smokers in our general popula-
tion to better contrast CVD risk perception between
smokers and non-smokers.
We assessed CVD risk perception asking about the risk
of developing a heart attack within 10 years. It would also
have been interesting to assess whether the self-perceived
risk of heart attack versus stroke would have been differ-
ent in smokers. However, we used the perceived risk of
heart attack as a proxy for the overall cardiovascular risk
and did not collect any data about stroke.
Patients with psychiatric disorders are known to be at
risk for substance abuse and have a high prevalence of
smoking, and consequently are exposed to high
Table 4 Determinants of underestimation according to the Framingham or PROCAM score
Variables
Framingham PROCAM
OR (95% CI) OR (95% CI)
Male gender 8.16 3.83 to 17.36 38.82 7.28 to 206.91
Age, years 1.06 1.02 to 1.09 1.22 1.15 to 1.30
Education ≥12 years 1.41 0.82 to 2.45 0.70 0.31 to 1.60
Unemployed or on social security 0.62 0.20 to 1.96 0.52 0.09 to 3.10
Hypertension 0.80 0.42 to 1.50 0.35 0.14 to 0.89
Hyperlipidaemia 2.71 1.47 to 5.01 4.49 1.59 to 12.70
Diabetes mellitus 13.93 3.83 to 50.66 192.49 24.82 to 1493.12
Cardiovascular medication 0.73 0.37 to 1.45 0.29 0.11 to 0.80
Obesity 1.06 0.99 to 1.13 1.10 1.00 to 1.21
Bold figures refer to the odds ratio.
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morbidity.19 These patients were excluded from the
CAROSS trial to ensure that consent was fully informed
and that participants would carefully follow the smoking
cessation advices. This understudied population would
beneﬁt from future trials speciﬁcally aimed at new
approaches for smoking cessation.
Clinicians widely use clinical scores to estimate CVD
risk in order to discuss primary prevention. This
approach is only efﬁcient when patients understand and
adhere to risk reduction therapy. Smokers represent a
challenge for general practitioners due to strong nico-
tine dependence and denial of personal risk from
smoking (optimistic bias).6
We found that 12–19% of smokers have a mispercep-
tion of their 10-year CVD risk in the form of an under-
estimation, which may hinder the efﬁciency of
interventions aimed at reducing or preventing CVD risk
factors. This could lead to an increase in morbidity and
mortality. Therefore, clinicians must be aware that about
one-ﬁfth of smokers underestimate their 10-year CVD
risk and that men as well as people suffering from hyper-
lipidaemia or diabetes are at increasing risk of underesti-
mating their 10-year CVD risk.
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